Artykuły w czasopismach na temat „HR-TKD”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „HR-TKD”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Haddad, Monoem, Anis Chaouachi, Del Wong, Carlo Castagna i Karim Chamari. "Heart Rate Responses and Training Load During Nonspecific and Specific Aerobic Training in Adolescent Taekwondo Athletes". Journal of Human Kinetics 29, nr 1 (1.09.2011): 59–66. http://dx.doi.org/10.2478/v10078-011-0040-y.
Pełny tekst źródłaHaddad, Monoem, Anis Chaouachi, Carlo Castagna, Del P. Wong, David G. Behm i Karim Chamari. "The Construct Validity of Session RPE During an Intensive Camp in Young Male Taekwondo Athletes". International Journal of Sports Physiology and Performance 6, nr 2 (czerwiec 2011): 252–63. http://dx.doi.org/10.1123/ijspp.6.2.252.
Pełny tekst źródłaHegde, Pranay S., Georgia Andrew, Gege Gui, Niveditha Ravindra, Devdeep Mukherjee, Zoe Wong, Jeffery J. Auletta i in. "Persistence of FLT3-TKD in Blood Prior to Allogeneic Transplant Is Associated with Increased Relapse and Death in Adults with AML in First Remission". Blood 142, Supplement 1 (28.11.2023): 2941. http://dx.doi.org/10.1182/blood-2023-180121.
Pełny tekst źródłaErnould, Clément, Benoît Beausir, Jean-Jacques Fundenberger, Vincent Taupin i Emmanuel Bouzy. "Global DIC approach guided by a cross-correlation based initial guess for HR-EBSD and on-axis HR-TKD". Acta Materialia 191 (czerwiec 2020): 131–48. http://dx.doi.org/10.1016/j.actamat.2020.03.026.
Pełny tekst źródłaErnould, Clément, Benoît Beausir, Jean-Jacques Fundenberger, Vincent Taupin i Emmanuel Bouzy. "Characterization at high spatial and angular resolutions of deformed nanostructures by on-axis HR-TKD". Scripta Materialia 185 (sierpień 2020): 30–35. http://dx.doi.org/10.1016/j.scriptamat.2020.04.005.
Pełny tekst źródłaDu, Juan, Richard F. Schlenk, Andrea Corbacioglu, Marianne Habdank, Claudia Scholl, Stefan Frohling, Lars Bullinger, Arnold Ganser, Hartmut Dohner i Konstanze Dohner. "RAS, KIT and FLT3 Gene Mutations in inv(16)/t(16;16)-Positive Acute Myeloid Leukemia (AML): Incidence and Relevance on Clinical Outcome." Blood 108, nr 11 (1.11.2006): 2303. http://dx.doi.org/10.1182/blood.v108.11.2303.2303.
Pełny tekst źródłaPaschka, Peter, Juan Du, Richard F. Schlenk, Verena I. Gaidzik, Lars Bullinger, Andrea Corbacioglu, Daniela Späth i in. "Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)". Blood 121, nr 1 (3.01.2013): 170–77. http://dx.doi.org/10.1182/blood-2012-05-431486.
Pełny tekst źródłaYu, Hongbing, Junliang Liu, Phani Karamched, Angus J. Wilkinson i Felix Hofmann. "Mapping the full lattice strain tensor of a single dislocation by high angular resolution transmission Kikuchi diffraction (HR-TKD)". Scripta Materialia 164 (kwiecień 2019): 36–41. http://dx.doi.org/10.1016/j.scriptamat.2018.12.039.
Pełny tekst źródłaAttar, Eyal C., Kati Maharry, Krzysztof Mrózek, Michael D. Radmacher, Susan P. Whitman, Peter Paschka, Christian Langer i in. "Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study." Blood 114, nr 22 (20.11.2009): 1616. http://dx.doi.org/10.1182/blood.v114.22.1616.1616.
Pełny tekst źródłaMohamedali, Azim M., Robert K. Hills, Erick E. Nasser, Atiyeh Abdallah, Sneha Shinde, Austin G. Kulasekararaj, Amanda Gilkes, Nicholas Lea, Alan K. Burnett i Ghulam J. Mufti. "Single Nucleotide Polymorphism Array (SNP-A) Karyotype Is the Best Predictor of Prognosis In Normal Cytogenetics Acute Myeloid Leukaemia (AML)". Blood 118, nr 21 (18.11.2011): 411. http://dx.doi.org/10.1182/blood.v118.21.411.411.
Pełny tekst źródłaHeinicke, Thomas, Myriam Labopin, Didier Blaise, Jaime Sanz, Ibrahim Yakoub-Agha, Thomas Cluzeau, Marco Ladetto i in. "Outcome of Allogeneic Stem Cell Transplantation in FLT3-TKD-Mutated AML - a Study on Behalf of the Acute Leukemia Working Party of the EBMT". Blood 142, Supplement 1 (28.11.2023): 4976. http://dx.doi.org/10.1182/blood-2023-174233.
Pełny tekst źródłaSantos, F. P., W. Qiao, J. E. Cortes, D. Jones, F. Ravandi, D. Verma, H. Kantarjian i G. Borthakur. "Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia (AML)". Journal of Clinical Oncology 27, nr 15_suppl (20.05.2009): 7015. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.7015.
Pełny tekst źródłaSchlenk, Richard F., Andrea Corbacioglu, Jürgen Krauter, Lars Bullinger, Michael Morgan, Daniela Späth, Irina Schäfer i in. "Gene Mutations as Predicitive Markers for Postremission Therapy in Younger Adults with Normal Karyotype AML." Blood 108, nr 11 (16.11.2006): 4. http://dx.doi.org/10.1182/blood.v108.11.4.4.
Pełny tekst źródłaDu, Juan, Richard F. Schlenk, Andrea Corbacioglu, Marianne Habdank, Claudia Scholl, Stefan Frohling, Lars Bullinger, Arnold Ganser, Hartmut Dohner i Konstanze Dohner. "Detection of RAS, KIT and FLT3 Gene Mutations in t(8;21)-Positive Acute Myeloid Leukemia (AML): Evaluation of the Clinical Relevance." Blood 108, nr 11 (1.11.2006): 2301. http://dx.doi.org/10.1182/blood.v108.11.2301.2301.
Pełny tekst źródłaXu, Yang, Zhen Yang, Hong Tian, Huiying Qiu, Aining Sun, Suning Chen i Wu Depei. "Hematopoietic Stem Cell Transplantation (HSCT) Benefits the Survival of Acute Myeloid Leukemia (AML) Patients with IDH1, NRAS and DNMT3A Mutations". Blood 120, nr 21 (16.11.2012): 1981. http://dx.doi.org/10.1182/blood.v120.21.1981.1981.
Pełny tekst źródłaTakahashi, Koichi, Elias J. Jabbour, Xuemei Wang, Hady Ghanem, Naveen Pemmaraju, Farhad Ravandi, Jorge E. Cortes i in. "Very High Rate of Leukemic Transformation and Poor Survival in Patients with Lower Risk Myelodysplastic Syndrome (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis". Blood 120, nr 21 (16.11.2012): 3802. http://dx.doi.org/10.1182/blood.v120.21.3802.3802.
Pełny tekst źródłaPaschka, Peter, Juan Du, Richard F. Schlenk, Verena I. Gaidzik, Lars Bullinger, Andrea Corbacioglu, Manuela Zucknick i in. "Type and Number of Secondary Molecular Lesions Improve Outcome Prediction in Acute Myeloid Leukemia (AML) with inv(16) or t(16;16): A Study of the German-Austrian AML Study Group (AMLSG)." Blood 114, nr 22 (20.11.2009): 824. http://dx.doi.org/10.1182/blood.v114.22.824.824.
Pełny tekst źródłaCocciardi, Sibylle, Nina Weiß, Maral Saadati, Sabrina Skambraks, Daniela Weber, Isabelle Schneider, Annika Meid i in. "The Genomic Landscape and Its Clinical Implication in NPM1-Mutated AML Patients: A Study within the AMLSG 09-09 Clinical Trial". Blood 142, Supplement 1 (28.11.2023): 4311. http://dx.doi.org/10.1182/blood-2023-185566.
Pełny tekst źródłaYoon, Jae-Ho, Hee-Je Kim, Byung Sik Cho, Seung-Ah Yahng, Seung-Hwan Shin, Sung-Eun Lee, Ki-Seong Eom i in. "High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL)". Blood 126, nr 23 (3.12.2015): 3842. http://dx.doi.org/10.1182/blood.v126.23.3842.3842.
Pełny tekst źródłaKnapper, Steven, Robert K. Hills, James D. Cavenagh, Lars Kjeldsen, Ann E. Hunter, Richard E. Clark, Michael Dennis i in. "A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience". Blood 124, nr 21 (6.12.2014): 3736. http://dx.doi.org/10.1182/blood.v124.21.3736.3736.
Pełny tekst źródłaPaschka, Peter, Guido Marcucci, Amy S. Ruppert, Susan P. Whitman, Krzysztof Mrózek, Kati Maharry, Christian Langer i in. "Wilms’ Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study". Journal of Clinical Oncology 26, nr 28 (1.10.2008): 4595–602. http://dx.doi.org/10.1200/jco.2007.15.2058.
Pełny tekst źródłaSilva, Wellington F., Fernanda Rodrigues Mendes, Marco Sartori, Maria Isabel A. Madeira, Katia B. Pagnano, Ana Beatriz F. Gloria, Elenaide C. Nunes i in. "Real-World Data for FLT3-Mutated Acute Myeloid Leukemia Patients Treated in Resource-Constrained Settings". Blood 142, Supplement 1 (28.11.2023): 5839. http://dx.doi.org/10.1182/blood-2023-187902.
Pełny tekst źródłaGrossmann, Vera, Claudia Haferlach, Susanne Schnittger, Ulrike Bacher, Franziska Poetzinger, Sandra Weissmann, Andreas Roller i in. "Acute Erythroid Leukemia (AEL) Can Be Separated Into Distinct Prognostic Subsets Based On Cytogenetic and Molecular Genetic Characteristics". Blood 120, nr 21 (16.11.2012): 1394. http://dx.doi.org/10.1182/blood.v120.21.1394.1394.
Pełny tekst źródłaSanford, David, Jorge E. Cortes, Farhad Ravandi, Wei Qiao, Keyur P. Patel, Thuyvan Hoang, Tapan Kadia, Hagop M. Kantarjian i Gautam Borthakur. "Prognostic Impact of Kinase Mutations and Minimal Residual Disease in Core-Binding Factor Leukemia". Blood 126, nr 23 (3.12.2015): 3828. http://dx.doi.org/10.1182/blood.v126.23.3828.3828.
Pełny tekst źródłaEisfeld, Ann-Kathrin, Guido Marcucci, Kati Maharry, Sebastian Schwind, Michael D. Radmacher, Deedra Nicolet, Heiko Becker i in. "MiR-3151, a Novel MicroRNA Embedded in BAALC, Is Only Weakly Co-Expressed with Its Host Gene and Independently Impacts on the Clinical Outcome of Older Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)". Blood 118, nr 21 (18.11.2011): 1462. http://dx.doi.org/10.1182/blood.v118.21.1462.1462.
Pełny tekst źródłaAly, Mai M. M., Mahesh Swaminathan, Katherine G. Akers, Seongho Kim, Harry Ramos, Jaroslaw P. Maciejewski i Suresh Kumar Balasubramanian. "A Systematic Review and Meta-Analysis Comparing Type I and II FLT3 Inhibitors in Relapsed/ Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome". Blood 138, Supplement 1 (5.11.2021): 1249. http://dx.doi.org/10.1182/blood-2021-148902.
Pełny tekst źródłaWhitman, Susan P., Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Dean Margeson, Kelsi B. Holland, Heiko Becker i in. "Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older [≥60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study." Blood 114, nr 22 (20.11.2009): 1579. http://dx.doi.org/10.1182/blood.v114.22.1579.1579.
Pełny tekst źródłaMosquera Orgueira, Adrian, Manuel Perez Encinas, Jose Angel Diaz Arias, Rebeca Rodriguez Veiga, Juan Miguel Bergua Burgues, Jesús Lorenzo Algarra, Carmen Botella i in. "The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial". Blood 142, Supplement 1 (28.11.2023): 974. http://dx.doi.org/10.1182/blood-2023-180482.
Pełny tekst źródłaDeneberg, Stefan, Michael Grövdal, Monika Jansson, Verena I. Gaidzik, Andrea Corbacioglu, Hareth Nahi, Sofia Bengtzen i in. "Different Incidence and Implications of DNA Hypermethylation in De Novo AML Compared to High-Risk MDS and AML Following MDS." Blood 112, nr 11 (16.11.2008): 3337. http://dx.doi.org/10.1182/blood.v112.11.3337.3337.
Pełny tekst źródłaJentzsch, Madlen, Marius Bill, Julia Schulz, Juliane Grimm, Stefanie Beinicke, Karoline Schubert, Janine Haentschel i in. "High Blood BAALC Copy Numbers Determined By Digital Droplet PCR at Timepoint of Allogeneic Transplantation in Complete Remission Predicts Relapse in Patients with Acute Myeloid Leukemia". Blood 128, nr 22 (2.12.2016): 517. http://dx.doi.org/10.1182/blood.v128.22.517.517.
Pełny tekst źródłaPaschka, Peter, Juan Du, Richard F. Schlenk, Lars Bullinger, Verena I. Gaidzik, Andrea Corbacioglu, Axel Benner i in. "Mutations in the Fms-Related Tyrosine Kinase 3 (FLT3) Gene Independently Predict Poor Outcome in Acute Myeloid Leukemia (AML) with t(8;21): A Study of the German-Austrian AML Study Group (AMLSG)." Blood 114, nr 22 (20.11.2009): 825. http://dx.doi.org/10.1182/blood.v114.22.825.825.
Pełny tekst źródłaSchroeder, Thomas, Christian Saure, Ingmar Bruns, Fabian Zohren, Akos G. Czibere, Nelly Nancy Safaian, Roland Fenk, Rainer Haas i Guido Kobbe. "Clinical Efficacy of Sorafenib in Patients with Acute Myeloid Leukemia (AML) and Activating FLT3-Mutations." Blood 114, nr 22 (20.11.2009): 2057. http://dx.doi.org/10.1182/blood.v114.22.2057.2057.
Pełny tekst źródłaPerl, Alexander E., Jessica K. Altman, Naoko Hosono, Pau Montesinos, Nikolai A. Podoltsev, Giovanni Martinelli, Catherine C. Smith i in. "Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib". Blood 136, Supplement 1 (5.11.2020): 22–23. http://dx.doi.org/10.1182/blood-2020-136395.
Pełny tekst źródłaStone, Richard M., Sumithra Mandrekar, Ben L. Sanford, Susan Geyer, Clara D. Bloomfield, Konstanze Dohner, Christian Thiede i in. "The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance])". Blood 126, nr 23 (3.12.2015): 6. http://dx.doi.org/10.1182/blood.v126.23.6.6.
Pełny tekst źródłaMushtaq, Muhammad Umair, Sibgha Gull Chaudhary, Guru Subramanian Guru Murthy, Aric C. Hall, Ehab L. Atallah i Ryan J. Mattison. "Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Relapsed/Refractory Acute Myeloid Leukemia". Blood 132, Supplement 1 (29.11.2018): 5246. http://dx.doi.org/10.1182/blood-2018-99-112204.
Pełny tekst źródłaWang, Jianxiang, Bin Jiang, Jian Li, Ligen Liu, Xin Du, Hao Jiang, Jianda Hu i in. "Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia". Blood 138, Supplement 1 (5.11.2021): 695. http://dx.doi.org/10.1182/blood-2021-145436.
Pełny tekst źródłaMarcucci, Guido, Kati Maharry, Klaus H. Metzeler, Stefano Volinia, Yue-Zhong Wu, Krzysztof Mrózek, Deedra Nicolet i in. "The Clinical Role of Micrornas (miRs) in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): miR-155 Upregulation Independently Identifies High-Risk Patients (Pts)". Blood 120, nr 21 (16.11.2012): 1387. http://dx.doi.org/10.1182/blood.v120.21.1387.1387.
Pełny tekst źródłaSchnittger, Susanne, Christiane Eder, Tamara Alpermann, Frank Dicker, Madlen Ulke, Alexander Kohlmann, Sabrina Kuznia, Wolfgang Kern, Torsten Haferlach i Claudia Haferlach. "WT1 Mutations Are Secondary Events In AML and Show Varying Frequencies Within Genetic Subgroups and Different Impact On Prognosis". Blood 122, nr 21 (15.11.2013): 2542. http://dx.doi.org/10.1182/blood.v122.21.2542.2542.
Pełny tekst źródłaLiévin, Raphaël, Nicolas Duployez, Loïc Vasseur, Juliette Lambert, Mael Heiblig, Mathilde Hunault, Claude Gardin i in. "Hyperleukocytosis Increases the Risk of Early Relapses Independently of Genetics in AML". Blood 142, Supplement 1 (28.11.2023): 4322. http://dx.doi.org/10.1182/blood-2023-173614.
Pełny tekst źródłaBalsat, Marie, Aline Renneville, Xavier Thomas, Alice Marceau, Stéphane De Botton, Olivier Nibourel, Emmanuel Raffoux i in. "NPM1 Minimal Residual Disease As Prognostic and Predictive Factor in Young Adults with Acute Myeloid Leukemia: a Study By the French ALFA Group". Blood 126, nr 23 (3.12.2015): 2581. http://dx.doi.org/10.1182/blood.v126.23.2581.2581.
Pełny tekst źródłaCappelli, Luca Vincenzo, Manja Meggendorfer, Constance Baer, Niroshan Nadarajah, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach i Alexander Höllein. "NPM1 Mutated AML Is Characterized By Pre-Leukemic Mutations and the Persistence and Acquisition of Co-Mutations in Molecular Remission Leads to Inferior Prognosis". Blood 132, Supplement 1 (29.11.2018): 996. http://dx.doi.org/10.1182/blood-2018-99-118286.
Pełny tekst źródłaAgrawal, Mridul, Andrea Corbacioglu, Peter Paschka, Daniela Weber, Verena I. Gaidzik, Nikolaus Jahn, Andrea Kündgen i in. "Minimal Residual Disease Monitoring in Acute Myeloid Leukemia (AML) with Translocation t(8;21)(q22;q22): Results of the AML Study Group (AMLSG)". Blood 128, nr 22 (2.12.2016): 1207. http://dx.doi.org/10.1182/blood.v128.22.1207.1207.
Pełny tekst źródłaHou, Hsin-An, Yuan-Yeh Kuo, Chieh-Yu Liu, Wen-Chien Chou, Ming Cheng Lee, Chien-Yuan Chen, Liang-In Lin i in. "DNMT3A Mutations in Acute Myeloid Leukemia-Stability During Disease Evolution and the Clinical Implication". Blood 118, nr 21 (18.11.2011): 409. http://dx.doi.org/10.1182/blood.v118.21.409.409.
Pełny tekst źródłaStrzalka, Piotr, Kinga Krawiec, Dariusz Jarych, Aneta Wiśnik, Michał Soin, Magdalena Góralska, Damian Mikulski i in. "Assessment of SIRT1-SIRT7 and TP53 Genes Expression in Patients with Acute Myeloid Leukemia". Blood 142, Supplement 1 (28.11.2023): 6048. http://dx.doi.org/10.1182/blood-2023-187756.
Pełny tekst źródłaLachowiez, Curtis A., Christopher A. Eide, Stephen E. Kurtz, Nicola Long, Manoj Rai, Wei Xie, Andy Kaempf i in. "Acute Myeloid Leukemia Differentiation State and Genotype Influence Anti-Apoptotic Protein Expression, Venetoclax Sensitivity, and Survival in AML". Blood 142, Supplement 1 (28.11.2023): 978. http://dx.doi.org/10.1182/blood-2023-179527.
Pełny tekst źródłaChan, Onyee, Najla Al Ali, Hammad Tashkandi, Austin Ellis, Somedeb Ball, Ling Zhang, Mohammad Hussaini i in. "Mutations Highly Specific for Secondary AML Are Associated with Poor Outcomes in Patients with NPM1-Mutated ELN Favorable Risk AML". Blood 138, Supplement 1 (5.11.2021): 686. http://dx.doi.org/10.1182/blood-2021-150759.
Pełny tekst źródłaYang, Hongbo, Yan Song, James D. Griffin, Manasee V. Shah, Jonathan Freimark i Andrew Chilelli. "Maintenance Therapy in Patients with FLT3-ITD-Mutation-Positive Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation: Real-World Survival". Blood 138, Supplement 1 (5.11.2021): 693. http://dx.doi.org/10.1182/blood-2021-145790.
Pełny tekst źródłaGetta, Bartlomiej M., Sean Devlin, Molly A. Maloy, Abhinita Mohanty, Maria Arcila, Martin S. Tallman, Ross L. Levine, Sergio A. Giralt i Mikhail Roshal. "Multicolor Flow Cytometry and Multi-Gene Next Generation Sequencing Are Complimentary and Highly Predictive for Relapse in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant". Blood 128, nr 22 (2.12.2016): 834. http://dx.doi.org/10.1182/blood.v128.22.834.834.
Pełny tekst źródłaPerl, Alexander, Harry P. Erba, Pau Montesinos, Radovan Vrhovac, Elzbieta Patkowska, Heeje Kim, Pavel Zak i in. "Quantum-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed through Induction (IND) and Consolidation (CONS) Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (nd) FLT3-ITD+ AML Patients (pts)". Blood 142, Supplement 1 (28.11.2023): 832. http://dx.doi.org/10.1182/blood-2023-186785.
Pełny tekst źródłaKrawiec, Kinga, Piotr Strzalka, Dariusz Jarych, Aneta Wiśnik, Michał Soin, Magdalena Góralska, Damian Mikulski i in. "Evaluation of Neddylation and Apoptosis-Related Gene Expression in Patients with Acute Myeloid Leukemia". Blood 142, Supplement 1 (28.11.2023): 5990. http://dx.doi.org/10.1182/blood-2023-181739.
Pełny tekst źródła